Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1461-1480 of 1,782 trials

SAPHO Syndrome: Etanercept Treatment Study

We are testing the safety and effectiveness of etanercept in patients with SAPHO syndrome who are already on standard treatments. This study aims to explore new treatment options for better management of their condition.

SAPHO Syndrome6-12 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesInfectious DiseasesRheumatology

Lymphoma Treatment: Loncastuximab Tesirine

We are studying a new treatment for patients with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma after CAR T-cell therapy. The goal is to see if it improves response rates and survival outcomes.

B-cell Non-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

ORE-001 for Underweight Elderly Individuals

We are studying whether ORE-001, an oral medication, can help underweight elderly people increase their food intake and improve their health. The trial compares its effects to a placebo to assess safety and overall well-being.

Underweight3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesEndocrinologyGastroenterologyInternal Medicine

Delayed Sleep-Wake Phase Disorder: Tasimelteon Study

We are investigating whether tasimelteon can help people with Delayed Sleep-Wake Phase Disorder fall asleep faster and improve their overall sleep quality compared to a placebo.

Delayed Sleep-Wake Phase Disorder≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteNeurologyPsychiatry

Systemic Sclerosis: Nintedanib and Tocilizumab Study

We are testing a combination of nintedanib and tocilizumab for patients with systemic sclerosis and interstitial lung disease. The goal is to see if this new treatment is more effective than standard therapies.

Systemic SclerosisSystemic Sclerosis with Interstitial Lung Disease1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPulmonologyRheumatology

Citalopram for Reflux Hypersensitivity and Functional Heartburn

We are studying whether adding citalopram to existing treatments helps patients with reflux hypersensitivity or functional heartburn who still have symptoms. This trial aims to improve symptom relief for those not fully responding to current therapies.

Gastroesophageal Reflux Disease3-6 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPsychiatry

CIDP: Riliprubart Treatment Study

We are studying the long-term safety and effectiveness of riliprubart for individuals with chronic inflammatory demyelinating polyneuropathy. This trial will help us understand how well it works in improving disability and strength.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Budesonide for Inflammation in Functional Dyspepsia

We are studying whether Budesonide can help reduce inflammation and improve symptoms in patients with functional dyspepsia. This trial will also look at its effects on quality of life and emotional well-being.

Functional Dyspepsia3-6 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementGastroenterology

Cervical Dystonia: Botulinum Toxin for Back Muscle Activity

We are studying abnormal muscle activity in the back of people with cervical dystonia. The trial will test whether botulinum toxin injections can help improve this condition and what side effects may occur.

Cervical Dystonia>2 yearsMonitoring phase (IV)Standard MedicinesCost ReimbursementInternal MedicineNeurology

Advanced Melanoma: New Treatment Combination

We are studying a new treatment approach for patients with advanced melanoma, combining immune therapies to see if it improves outcomes and reduces side effects. This trial aims to understand how well these treatments work together.

Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Multiple Myeloma: Fluciclovine PET/CT Imaging Study

We are investigating a new imaging method for multiple myeloma patients to see how it compares to standard imaging. This study aims to understand its effectiveness and safety in detecting the disease.

Multiple MyelomaEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncologyOtolaryngology

Multiple Myeloma: Isatuximab Combination Therapy

We are studying a new treatment combining isatuximab with other medications for patients with newly diagnosed multiple myeloma who cannot undergo a transplant. The goal is to see how effective and safe this treatment is, and how it impacts patients' lives.

Newly Diagnosed Transplant Ineligible Multiple Myeloma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

ELGN-2112 for Intestinal Malabsorption in Preterm Infants

We are studying whether ELGN-2112 can help preterm infants with intestinal malabsorption achieve full feeding sooner and reduce the risk of serious complications. This trial compares the new treatment to a placebo to assess its safety and effectiveness.

Intestinal Malabsorption>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Bladder Cancer: Intravesical Gemcitabine Treatment

We are studying the effectiveness and safety of a drug called gemcitabine for patients with low-grade bladder cancer. This trial aims to see how well it works in treating this specific type of cancer.

Bladder Cancer≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Heart Procedure: Comparing Blood Thinners

We are studying how two different blood-thinning treatments affect blood clotting in patients undergoing closure of heart defects. This may help us understand which treatment is safer and more effective after the procedure.

Patent Foramen Ovale (PFO) / Atrial Septum Defect (ASD)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Rectal Cancer: Atezolizumab and Bevacizumab After Radiotherapy

We are studying a new treatment for low- to intermediate-risk rectal cancer to see if it helps prevent disease relapse and preserves organ function. The trial also evaluates the safety of this approach.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Menstrual Migraine: Rimegepant Study

We are investigating whether Rimegepant can help prevent menstrual migraines in women aged 18 to 45. This study compares its effects to a placebo to see if it reduces migraine frequency and improves quality of life.

Menstrual Migraine6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesGynecology and ObstetricsNeurology

Cervical Dysplasia: Improving Diagnosis with Estrogen

We are studying whether vaginal estrogen can improve the detection of precancerous cervical lesions in women aged 50 and older. This may help reduce the risk of cervical cancer and improve follow-up care.

HPV Positive with Cervical DysplasiaMonitoring phase (IV)Standard MedicinesGynecology and ObstetricsInternal Medicine

Sarcopenia Treatment: Nandrolone and Therapy

We are studying whether nandrolone, along with physiotherapy and diet, can improve muscle strength in people with sarcopenia. This research aims to find effective treatments for muscle loss.

Sarcopenia≤3 monthsEfficacy phase (II)Standard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Ovarian Cancer: Mirvetuximab Soravtansine Study

We are evaluating different dosing schedules of mirvetuximab soravtansine for patients with advanced ovarian, peritoneal, or fallopian tube cancers. This study aims to find the safest and most effective way to administer the treatment.

Advanced Ovarian and Fallopian Tube Cancer6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology